CHF Solutions (NASDAQ:CHFS) Rating Lowered to Hold at ValuEngine

ValuEngine cut shares of CHF Solutions (NASDAQ:CHFS) from a buy rating to a hold rating in a report published on Monday, February 4th.

Separately, Zacks Investment Research cut CHF Solutions from a buy rating to a hold rating in a research report on Tuesday, October 23rd.

CHFS stock traded up $0.06 during trading on Monday, hitting $9.06. 36,732 shares of the company traded hands, compared to its average volume of 21,650. The stock has a market cap of $4.57 million, a P/E ratio of -0.21 and a beta of 2.59. CHF Solutions has a 1 year low of $5.60 and a 1 year high of $65.80.

CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings data on Wednesday, February 20th. The company reported ($8.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($7.70) by ($0.67). The business had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $1.61 million. CHF Solutions had a negative net margin of 340.78% and a negative return on equity of 165.74%. Research analysts anticipate that CHF Solutions will post -18.88 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CHFS. Vanguard Group Inc acquired a new position in shares of CHF Solutions in the 3rd quarter valued at $39,000. Dimensional Fund Advisors LP acquired a new position in CHF Solutions during the 2nd quarter worth about $161,000. Finally, Wexford Capital LP lifted its stake in CHF Solutions by 176.9% during the 3rd quarter. Wexford Capital LP now owns 391,809 shares of the company’s stock worth $334,000 after acquiring an additional 250,300 shares in the last quarter.

About CHF Solutions

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Read More: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply